Lakewood-Amedex Biotherapeutics Announces Its Nu-3 Gel Was Well-Tolerated And Data Support Clinical Dose Selection For Its Upcoming Phase 2a Trial

뉴스 본문을 불러오고 있어요.

Lakewood-Amedex Biotherapeutics Announces Its Nu-3 Gel Was Well-Tolerated And Data Support Clinical Dose Selection For Its Upcoming Phase 2a Trial | 웨이프 WAPE

Lakewood-Amedex Biotherapeutics Announces Its Nu-3 Gel Was Well-Tolerated And Data Support Clinical Dose Selection For Its Upcoming Phase 2a Trial

기사 요약

관련 종목

댓글 —